On August 6, Oscar Health, Inc. declined 9.25% in regular trading, trading at $27.13/share, with turnover of $89.26 million. The stock had surged over 16% in pre-market trading before reversing sharply after the open.

The company reported Q2 EPS of $1.10, dramatically beating the analyst consensus estimate of $0.42-$0.49 and swinging from a loss of $0.89 per share in the year-ago period. Revenue reached $4.88 billion, up 70.6% year-over-year and exceeding the $4.73-$4.75 billion estimate. Total membership grew 46% to 2.963 million. Despite the strong operational performance, the company merely reaffirmed its full-year revenue guidance of $18.7 billion to $19.0 billion without an upward revision, disappointing investors who anticipated a raise given the magnitude of the Q2 beat.

The sharp intraday reversal reflects classic profit-taking dynamics, as market participants who had bid up shares aggressively in pre-market moved to lock in gains once the unchanged outlook signaled limited near-term upside catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)